Cellectar's Iopofosine I 131 Shows Positive Data In Waldenström Macroglobulinemia
(RTTNews) - Tuesday, Cellectar Biosciences (CLRB) said a Phase 2 CLOVER WaM subset analysis showed encouraging efficacy for iopofosine I 131 in patients with Waldenström macroglobulinemia who were refractory or resistant to BTK inhibitor therapy.